- Home
- GBR vs CLDI Comparison
GBR vs CLDI Comparison
Compare GBR & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | CLDI |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | GBR | CLDI |
|---|---|---|
| Price | $0.74 | $0.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 47.5K | ★ 2.0M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.16 | N/A |
| 52 Week Low | $0.65 | $0.16 |
| 52 Week High | $1.78 | $7.32 |
Technical Indicators
Market Signals| Indicator | GBR | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 28.84 |
| Support Level | $0.67 | N/A |
| Resistance Level | $0.84 | $0.20 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 23.81 | 24.94 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.